牛熊異動 | 上調目標價,聯想認購證漲170%
瑞銀上調聯想集團(00992.HK)目標價至7港元,評級“買入”,聯想集團今日股價大漲超5%,看漲衍生品聯想高盛零乙購A(13277.HK)漲超170%。
瑞銀發表報告,預期聯想集團在近期會繼續跑贏全球電腦行業,由於擁有強大的售後服務支持,估計集團市佔率會有增長機會。再者,集團亦有強勁的採購能力,在零件供應緊張下未來一至兩季應可有相對更佳的定位。該行上調聯想集團股份目標價,由6.5元升至7元,評級維持“買入”,並調升集團2021至2023財年每股盈利預測分別28%、8%及6%,以反映在良好控制經營開支下盈利有潛在上升空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.